DJ ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.
ABIVAX
ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.
11-Oct-2024 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Abivax Announces Termination of Liquidity Contract and Publishes End of Contract Statement
PARIS, France, October 11, 2024, 6:00 p.m. (CEST) - Abivax SA (Euronext Paris & Nasdaq: ABVX) ("Abivax" or the "Company
"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural
regulatory mechanisms to modulate the immune response in patients witch chronic inflammatory diseases, today announced
that it has ended the liquidity contract signed on February 4, 2019 with TRADITION SECURITIES AND FUTURE (TSAF SA). The
termination is effective from September 30, 2024, after the close of Euronext market.
On the termination date of this contract, the following assets appeared on the liquidity account:
-- 0 shares
-- EUR434,377.26 in cash
As a reminder, for the latest half-year statement as of June 30, 2024, the following assets appeared on the liquidity
account:
-- 11,431 shares
-- EUR313,753.00 in cash
And between July 1st, 2024, and September 30, 2024, included:
Traded volume:
Buy side EUR12,014.60 10 transactions
1,070 shares
Traded volume:
Sell side EUR132,638.86 26 transactions
12,501 shares
Moreover, the following resources were allocated to the liquidity contract for its implementation beginning June 26 th, 2015 (date of the initial contract entered into between the Company and TSAF SA, which was replaced by the above-mentioned contract):
-- 0 shares
-- EUR1,000,000 in cash
The liquidity account returned EUR500,000.00 in cash to Abivax on April 15, 2020.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax' s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX.
Contacts
Investor Relations France Seitosei -- Actifin
Abivax Abivax
Ghislaine Gasparetto
Finance department Investor Relations
ghislaine.gasparetto@seitosei-actifin.com Patrick Malloy
Didier Blondel patrick.malloy@abivax.com
didier.blondel@abivax.com +33 6 21 10 49 24 +1 847 987 4878
+33 1 53 83 08 41
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: 20241011_Abivax_Termination of liquidity contract and end of contract statement
=-------------------------------------------------------------------------------------------------------
Language: English
Company: ABIVAX
5, Rue de La Baume
75008 Paris
France
E-mail: info@abivax.de
Internet: www.abivax.de
ISIN: FR0012333284
Euronext Ticker: ABVX
AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID: 2007167
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2007167 11-Oct-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2007167&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face
(END) Dow Jones Newswires
October 11, 2024 12:00 ET (16:00 GMT)
